Menu

Gene Linked to Pain Insensitivity

People with a congenital disorder that makes them unable to feel pain have mutations in a histone-modifying gene. 

May 27, 2015
Kerry Grens

PIXABAY, GERALTBy analyzing the DNA of people who have been insensitive to pain since birth, researchers have homed in on an epigenetic regulator tied to the disorder. Mutations in PRDM12, a gene that appears important for the proper development of sensory neurons, cripple its ability to modify histones, researchers reported in Nature Genetics this week (May 25).

“We are very hopeful that this new gene could be an excellent candidate for drug development, particularly given recent successes with drugs targeting chromatin regulators in human disease,” Ya-Chun Chen from the University of Cambridge who led the work said in a statement.

As The Guardian reported, two other genes, SCN9A and SCN11A, were already associated with congenital insensitivity to pain. Both encode sodium channels. In the latest study, a large group of collaborators analyzed DNA from 11 families with members who have the condition. Among the affected family members, the research team identified 10 different mutations within PRDM12, each of which inhibited proper functioning of the protein. Furthermore, knocking down the gene’s ortholog in frog embryos disrupted neurogenesis during development.

“PRDM12 is essential for the sensing of pain in humans, as pathogenic mutations cause a congenital loss of pain perception. Our data imply that the pathological mechanism involves a loss of control of histone modification during critical points in nociceptor genesis,” the authors wrote in their report.

According to GenomeWeb, “based on these findings, those involved in the study speculated that it may be possible to tap into such pathways both to understand conditions such as [congenital insensitivity to pain] and develop strategies for treating individuals who experience high pain levels and/or long-lingering pain.”

 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.